Table 5.
Summary of cardiotoxicity in retrospective pediatric assessments.
| CD19-CAR-T Cardiovascular Events | Shalabi et al. (2020) [28] | Burstein et al. (2018) [29] | Fitzgerald et al. (2017) [30] |
|---|---|---|---|
| Patient Population | Pediatric (n = 52) | Pediatric (n = 98) | Pediatric (n = 39) |
| Treatment Indication | |||
| B-ALL | 50 (96.1%) | 90 (97%) | 39 (100%) |
| NHL | 2 (3.9%) | 1 (1%) | 0 |
| Multiple Myeloma | 0 | 0 | 0 |
| T-ALL | 0 | 1 (1%) | 0 |
| PML | 0 | 1 (1%) | 0 |
| CRS Grading System | Penn Criteria [12] ASTCT Consensus Criteria [14] |
Penn Criteria [12] | Penn Criteria [12] |
| Cardiotoxic Events | |||
| Pre-existing Cardiomyopathy/Structural Disease/Arrhythmia | 6 (11.5%) | 10 (11%)/1(5%) | NR |
| Hypotension Requiring Inotropic Support | 9 (24.3%) | 24 (24%) | 13 (33%) |
| Troponemia | NR | NR | NR |
| Ventricular Systolic Dysfunction | 6 (11.5%) | 10 (10%) | 1 (2%) |
| Tachycardia | 36 (69.2%) | NR | NR * |
| Arrhythmia | NR | NR | NR |
| ST segment changes | NR | 6 (6%) | NR |
| Cardiac Arrest/ Cardiac Death | 1 (2.7%) | 0 | NR |
| Required Tocilizumab | 14 (37.8%) | 21 (21%) | 13 (33%) |
* Number with tachycardia not reported. B-ALL: B-cell Acute Lymphoblastic Leukemia; NHL: non-Hodgkin Lymphoma; T-ALL: T-cell Acute Lymphoblastic Leukemia; PML: Primary Mediastinal Large B-cell Lymphoma.